Interactions between life expectancy and the incidence and mortality rates of cancer in China: a population-based cluster analysis

Xiuying Gu1, Rongshou Zheng2, Changfa Xia2, Hongmei Zeng2, Siwei Zhang2, Xiaonong Zou2, Zhixun Yang2, He Li2 and Wanqing Chen2*

Abstract

Background: The relationship between cancer and life expectancy is well established in both developed and developing countries. China is a vast country with significant geographical differences in population structure and healthcare, and thus provides a unique opportunity to analyze the complex relationship between life expectancy and cancer incidence and mortality rates.

Methods: Cancer data were extracted for a total of 255 units (cities or counties) from the 2013 National Central Cancer Registry. Life expectancy data at the unit level were obtained from the National Centers for Disease Control and Prevention. Linear regression analysis was used to analyze the relationship between life expectancy and crude incidence and mortality rates of cancer. In a separate analysis, life expectancy was rated as low (< 76.0 years), middle (76–80 years), or high (> 80 years).

Results: Overall, the cancer incidence and mortality rates positively correlated with life expectancy in both sexes (R at 0.37 and 0.50, P < 0.001). The correlation was significant for the following cancers: lung, colorectal, prostate, bladder and pancreas, as well as for lymphoma in men (R 0.36–0.58, P < 0.001), lung, breast, colorectal, thyroid, uterus, and ovary in women (R 0.18–0.51, P < 0.001). We failed to observe an association between upper gastrointestinal cancer and life expectancy. The number of cities/counties with low, middle and high life expectancy levels were 110, 101 and 44, respectively. The highest age-standardized cancer incidence rate was observed in areas with a high life expectancy level (192.83/100,000). The highest age-standardized mortality rate was in areas with the lowest life expectancy (118.44/100,000). Cancers of the stomach, liver and esophagus are major cancer types in areas with low and middle life expectancy. In contrast, areas with high life expectancy had high incidence and mortality rates of colorectal cancer, breast cancer in women and prostate cancer in men.

Conclusions: Longer life expectancy is associated with higher overall cancer incidence and mortality in China. The cancer pattern also varies substantially across areas with different life expectancy levels. Life expectancy levels must be considered when developing strategies to prevent and treat cancers.

Keywords: Cancer, Incidence, Mortality, Life expectancy, China

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Cancer is a major public health problem worldwide [1, 2]. The majority of cancer types are more common in elderly populations. The relationship between cancer and life expectancy in the general population has been extensively studied [3–6]. The results provided consistent evidence for differing cancer profiles across life expectancy levels. In particular, cancer is associated with an aging population and socioeconomic development. Aging populations have led to major changes in the structure of the global population and in the scale of the cancer problem worldwide [7]. The United Nations Development Program (UNDP) has now incorporated life expectancy as a component of the Human Development Index (HDI) to evaluate the influence of social development on health issues (including cardiovascular diseases and cancer) across different countries [8–10].

Global life expectancy has increased by 5 years since 2000, with an increasingly narrower gap between high- and low-income countries [8]. In China, the average life expectancy in 2015 was 76.34 years (73.64 for men and 79.43 for women); up 5 years from 2000 [11]. Despite the rapidly increasing life expectancy, overall cancer incidence has been relatively stable, with decreasing age-standardized mortality rates in both men and women [2, 12–14]. The cancer pattern in China, however, is rather different from developed countries [15]. Also, China is a vast country with significant differences in population structure and healthcare, and thus provides a unique opportunity to analyze the complex relationship between cancer incidence, mortality and life expectancy, with potential relevance on a global scale.

Materials and methods
Data source
Cancer data were retrieved from the National Central Cancer Registry (NCCR). A total of 255 units (cities or counties) were included in the analysis, that covered 31 provinces, 88 cities and 167 counties. The total population covered by NCCR was 226,494,490 (114,860,339 men and 111,634,151 women) and accounted for 16.65% of the national population at the end of 2013. Life expectancy data were obtained from the National Centers for Disease Control and Prevention (NCDC). Life expectancy was low (<76 years) in 110 units, 101 units in the middle (76–80 years) and high (>80 years) in 44 units. Life expectancy levels, based on geographical location, are shown in Fig. 1.

Quality control
Cancer data were collected, audited and maintained by the NCCR according to the standards set forward by the “Guideline for Chinese Cancer Registration”, “Cancer Incidence in Five Continents Volume IX”, as well as relevant data quality criteria by the International Agency for Research on Cancer/International Association of Cancer Registries (IARC/IACR) [16]. The assessments of quality measures include, but are not limited to, the proportion of morphologic verification (MV%), the percentage of cancer cases identified with death certification only (DCO%), the mortality (M) to incidence (I) ratio (M/I), the percentage of uncertified cancers (UB%). The MV%, DCO%, and M/I ratio of overall indicators in this analysis were 68.04%, 1.74% and 0.62%, respectively.

Statistical analysis
For descriptive analysis, the 255 units (cities/counties) were divided into three categories and based on the average life expectancy based on the 2009 report by the National Population Census [11]: low, middle, and high using 76 and 80 years of age as the cutoff points. A linear regression model (considering life expectancy as a continuous variable) was used to estimate the relationship between crude incidence and mortality rates of cancer and life expectancy using the data for each city/county. A sex-stratified analysis was conducted. A separate set of correlation analyses were conducted to analyze the relationship between each of the top 10 cancers with life expectancy. The Chinese population in 2000 and the World Segi’s population were used to calculate age-standardized rates. Softwares for data checking and evaluation included MS-Excel, IARCrgTools2.05 issued by International Agency for Research on Cancer (IARC) and International Association of Cancer Registries (IACR) [17]. All statistical analyses were conducted using SAS (SAS Institute Inc.; Cary, NC, USA).

Results
Linear regression analysis between cancer data and life expectancy
In both men and women, life expectancy correlated positively with both overall cancer incidence ($R_{\text{male incidence}} = 0.45$; $R_{\text{female incidence}} = 0.50$, $P<0.001$ for both men and women) and mortality ($R_{\text{male mortality}} = 0.42$, $R_{\text{female mortality}} = 0.37$, $P<0.001$ for both men and women) (Fig. 2).

The correlation between life expectancy and the incidence of the top 10 cancers are shown in Fig. 3. In men, life expectancy correlated positively with the incidence of cancers in the lungs ($R=0.36$, $P<0.001$), colorectum ($R=0.54$, $P<0.001$), prostate ($R=0.58$, $P<0.001$), bladder ($R=0.43$, $P<0.001$), pancreas ($R=0.50$, $P<0.001$) and lymphoma ($R=0.43$, $P<0.001$). The correlation was most robust for prostate cancer ($R=0.58$, $P<0.001$). Life expectancy did not correlate with cancers of the stomach, liver, esophagus, brain and central nervous system (CNS). In women, life expectancy correlated positively
with the incidence of cancers in the lungs, breast, colorectum, thyroid, uterus and ovary ($R$ from 0.18 to 0.51, all $P < 0.01$). The correlation was most robust for colorectal cancer ($R = 0.51, P < 0.001$).

The correlation between life expectancy and cancer mortality of the top 10 cancers are shown in Fig. 4. In men, life expectancy was correlated positively with the mortality in cancers of the lungs, liver, colorectum, pancreas, prostate, leukemia, and lymphoma ($R$ from 0.16 to 0.55, all $P < 0.05$), but not cancers of the upper gastrointestinal tract ($R = 0.01, P = 0.419$). The correlation was most robust for pancreatic cancer ($R = 0.55, P < 0.001$).

In women, life expectancy correlated positively with the mortality in cancers of the lungs, colorectum, breast, pancreas and leukemia ($R$ from 0.23 to 0.53, all $P < 0.05$), but not cancers of the liver, stomach, esophagus, brain and CNS and cervix. The association between life expectancy and less common types of cancer varied substantially. Such as, in both sexes, life expectancy correlated positively with the incidence of oral, nasopharynx, gallbladder, kidney and melanoma of the skin cancers ($R$ from 0.07 to 0.52, all $P < 0.05$). And there were the same associations between life expectancy and mortality in those cancers ($R$ from 0.05 to 0.45, all $P < 0.05$) (Figs. 5, 6).

### Incidence

#### Overall incidence

Overall cancer incidence rates in the areas with different life expectancy levels are shown in Table 1. Areas with high life expectancy (> 80 years) had a high crude incidence rate, followed by areas with middle (76–80 years) and low (< 76 years) life expectancy levels. There was a U-shaped association between age-standardized incidence rates and life expectancy levels; areas with a middle

![Fig. 1](image-url)
life expectancy level had the lowest age-standardized incidence rate by world standard population (ASIRW). The patterns of crude incidence rates in men and women were similar to the overall sample that included both sexes. However, after adjusting for age, cancer incidence rates in men in low life expectancy level areas was higher than that in high and middle level areas. In women, the adjusted incidence rate was much higher in high life expectancy level areas than that of low and middle life expectancy level areas.

**Top ten leading cancer types**

Incidence rates for the top 10 cancers in the areas with different life expectancy levels are shown in Table 1. The overall analysis showed that lung cancer is the most common cancer in both sexes. ASIRW was significantly higher in low life expectancy areas (37.41/100,000) than in high life expectancy level areas (34.90/100,000). Cancers of the stomach, liver, and esophagus were all in the top 5 list in both low and middle life expectancy level areas. Similar to that of lung cancer, the ASIRW in middle life expectancy areas were lower than in low life expectancy areas (21.66 vs. 28.76/10,000, 18.56 vs. 22.25/10,000, and 16.27 vs. 20.58/10,000) for the three types of cancers, respectively. In high life expectancy level areas, colorectal cancer ranked second which was higher than middle and low life expectancy areas. And incidence rates of breast and thyroid cancers in women increased stepwise from low to high expectancy level areas.

Cancer types varied significantly among areas with different life expectancy. In low and middle life expectancy level areas, the most common cancers in men were the cancers of the lung, stomach, liver and esophagus. In
Fig. 3 Correlation between life expectancy and incidence rates for the top ten leading types of cancers, stratified by sex. The top ten leading types of cancer incidence were published by overall cancer registration data in 2013 and published previously on Cancer Letters (Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013 [12]. Cancer Lett. 2017;401:63–71)
Fig. 4 Correlation between life expectancy and mortality rates for the top ten leading types of cancers, stratified by sex. The top ten leading types of cancer death were published by overall cancer registration data in 2013 and published previously on Cancer Letters (Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in china, 2013 [J]. Cancer Lett. 2017;401:63–71)
Fig. 5 Correlation between life expectancy and incidence rates in others cancers, stratified by sex
Fig. 6 Correlation between life expectancy and mortality rates in others cancers, stratified by sex
Table 1  Top 10 cancer incidence in three life expectancy levels areas of China, 2013

| Rank | Gender | Low life expectancy level areas | Middle life expectancy level areas | High life expectancy level areas |
|------|--------|---------------------------------|------------------------------------|----------------------------------|
|      |        | Site | Incidence (1/10^5) | Proportion (%) | ASR* (1/10^5) | Site | Incidence (1/10^5) | Proportion (%) | ASR* (1/10^5) | Site | Incidence (1/10^5) | Proportion (%) | ASR* (1/10^5) |
| 0    | Both   | All sites | 242.77 | 100.00 | 186.91 | All sites | 262.81 | 100.00 | 179.00 | All sites | 339.61 | 100.00 | 192.83 |
| 1    |        | Lung | 49.39 | 20.34 | 37.41 | Lung | 55.64 | 21.17 | 36.88 | Lung | 64.44 | 19.56 | 34.90 |
| 2    |        | Stomach | 37.50 | 15.45 | 28.76 | Stomach | 32.36 | 12.31 | 21.66 | Stomach | 38.42 | 11.31 | 20.57 |
| 3    |        | Liver | 29.17 | 12.01 | 22.25 | Liver | 27.42 | 10.43 | 18.56 | Liver | 31.83 | 9.37 | 17.08 |
| 4    |        | Esophagus | 26.87 | 11.07 | 20.58 | Esophagus | 24.42 | 9.29 | 16.27 | Esophagus | 56.75 | 8.35 | 34.59 |
| 5    |        | Colorectum | 17.85 | 7.35 | 13.60 | Colorectum | 22.61 | 8.60 | 15.12 | Colorectum | 28.08 | 8.27 | 15.83 |
| 6    | Men    | Breast | 28.36 | 5.67 | 21.26 | Breast | 37.05 | 6.94 | 25.18 | Breast | 17.54 | 5.16 | 12.19 |
| 7    |        | Cervix | 16.24 | 3.25 | 12.19 | Thyroid | 81.7 | 3.11 | 5.89 | Thyroid | 16.14 | 4.75 | 8.55 |
| 8    |        | Brain, CNS | 6.79 | 2.80 | 5.53 | Cervix | 142.1 | 2.66 | 9.71 | Cervix | 10.16 | 2.99 | 5.21 |
| 9    |        | Leukemia | 4.83 | 1.99 | 4.46 | Brain, CNS | 6.21 | 2.36 | 4.63 | Brain, CNS | 8.81 | 2.59 | 5.82 |
| 10   | Men    | Pancreas | 4.03 | 1.66 | 3.06 | Pancreas | 6.10 | 2.32 | 4.04 | Pancreas | 8.74 | 2.57 | 5.21 |
| 0    |        | All sites | 276.05 | 100.00 | 220.73 | All sites | 294.24 | 100.00 | 207.57 | All sites | 365.39 | 100.00 | 209.60 |
| 1    |        | Lung | 65.90 | 23.87 | 52.32 | Lung | 73.76 | 25.07 | 51.26 | Lung | 86.09 | 23.56 | 47.22 |
| 2    |        | Stomach | 51.72 | 18.74 | 41.26 | Stomach | 44.90 | 15.26 | 31.41 | Stomach | 43.61 | 11.94 | 24.27 |
| 3    |        | Liver | 41.18 | 14.92 | 32.42 | Liver | 39.91 | 13.56 | 27.97 | Liver | 43.53 | 11.91 | 24.21 |
| 4    |        | Esophagus | 35.64 | 12.91 | 28.47 | Esophagus | 33.74 | 11.47 | 23.61 | Esophagus | 41.14 | 11.26 | 24.16 |
| 5    |        | Colorectum | 19.84 | 7.19 | 15.75 | Colorectum | 25.67 | 8.72 | 17.87 | Colorectum | 23.95 | 6.55 | 13.38 |
| 6    |        | Brain, CNS | 6.97 | 2.52 | 5.79 | Bladder | 7.81 | 2.66 | 5.36 | Bladder | 16.80 | 4.60 | 8.51 |
| 7    |        | Bladder | 5.37 | 1.94 | 4.21 | Pancreas | 6.95 | 2.36 | 4.83 | Pancreas | 13.24 | 3.62 | 7.08 |
| 8    |        | Leukemia | 5.29 | 1.92 | 4.97 | Prostate | 6.72 | 2.28 | 4.48 | Prostate | 11.26 | 3.08 | 6.13 |
| 9    |        | Lymphoma | 4.72 | 1.71 | 3.89 | Lymphoma | 6.17 | 2.10 | 4.53 | Kidney | 10.23 | 2.80 | 604 |
| 10   |        | Pancreas | 4.56 | 1.65 | 3.61 | Leukemia | 6.00 | 2.04 | 5.24 | Lymphoma | 9.96 | 2.72 | 612 |
# Table 1 (continued)

| Rank | Gender | Low life expectancy level areas | Middle life expectancy level areas | High life expectancy level areas |
|------|--------|---------------------------------|------------------------------------|----------------------------------|
|      |        | Site               | Incidence (1/10⁵) | Proportion (%) | ASRᵃ | Site               | Incidence (1/10⁵) | Proportion (%) | ASRᵃ | Site               | Incidence (1/10⁵) | Proportion (%) | ASRᵃ |
| 0    | Women  | All sites         | 207.45             | 100.00          | 154.66 | All sites         | 230.36             | 100.00          | 152.91 | All sites         | 313.81             | 100.00          | 178.58 |
| 1    |        | Lung              | 31.86              | 15.36           | 22.94  | Breast            | 37.05              | 16.08           | 25.18  | Breast            | 56.75              | 18.08           | 34.59  |
| 2    |        | Breast            | 28.36              | 13.67           | 21.26  | Lung              | 36.93              | 16.03           | 23.28  | Lung              | 46.78              | 14.91           | 23.36  |
| 3    |        | Stomach           | 22.41              | 10.80           | 16.31  | Colorectum        | 19.46              | 8.45            | 12.51  | Colorectum        | 33.24              | 10.59           | 17.10  |
| 4    |        | Esophagus         | 17.58              | 8.47            | 12.79  | Stomach           | 19.42              | 8.43            | 12.32  | Thyroid           | 26.34              | 8.39            | 18.22  |
| 5    |        | Liver             | 16.42              | 7.91            | 11.98  | Esophagus         | 14.81              | 6.43            | 9.18   | Stomach           | 20.13              | 6.41            | 10.37  |
| 6    |        | Cervix            | 16.24              | 7.83            | 12.19  | Liver             | 14.54              | 6.31            | 9.27   | Cervix            | 15.25              | 4.86            | 9.74   |
| 7    |        | Colorectum        | 15.73              | 7.58            | 11.50  | Cervix            | 14.21              | 6.17            | 9.71   | Liver             | 15.02              | 4.79            | 7.67   |
| 8    |        | Uterus            | 7.75               | 3.74            | 5.84   | Thyroid           | 12.74              | 5.53            | 9.12   | Uterus            | 12.02              | 3.83            | 7.14   |
| 9    |        | Brain, CNS        | 6.60               | 3.18            | 5.28   | Uterus            | 8.31               | 3.61            | 5.66   | Brain, CNS        | 9.71               | 3.09            | 6.18   |
| 10   |        | Ovary             | 6.12               | 2.95            | 4.78   | Ovary             | 7.26               | 3.15            | 5.11   | Ovary             | 9.17               | 2.92            | 5.77   |

ⁿ ASR: age-standardized incidence rate (Segi’s Standard Population)
high life expectancy level areas, colorectal cancer was also very common; the ASIRW of prostate and bladder cancers was also higher than in low and middle level areas. In women, cancers of the lung, breast, stomach, esophagus and liver were the most common types in low life expectancy level areas. In middle life expectancy level areas, cancers of the breast, lung, colorectum, stomach, and esophagus were the most common cancers in women. In high life expectancy level areas, cancers of the breast, lung, colorectum, thyroid and stomach were the most common cancers.

Mortality
Overall mortality
Cancer mortality rates in areas with different life expectancy levels are shown in Table 2. High life expectancy level areas had higher crude mortality rates, followed by middle and then low life expectancy level areas. Stratified analysis based on sex produced similar findings: the crude cancer mortality rate in high life expectancy level areas was higher than that in middle and low-level areas. However, the age-standardized mortality rate correlated negatively with life expectancy, with the low life expectancy level areas having the highest age-standardized mortality rate by world standard population (ASMRW). The patterns of ASMRW in men and women were similar to the overall analysis that included both men and women.

Top ten leading cancer types
Mortality rates for the top 10 leading cancers in areas with different life expectancy levels are shown in Table 2. Lung cancer was the leading cause of cancer death regardless of life expectancy levels in both men and women. Other cancer types with high mortality rates included cancers of the stomach, liver, esophagus and colorectum. The ASMRW of colorectal and pancreatic cancers in high life expectancy level areas was significantly higher than that in low and middle level areas.

The pattern of ASMRW in men was similar to that in the overall analysis that included both sexes. In low and middle life expectancy level areas, stomach cancer ranked second in cancer mortality in women, followed by liver and esophageal cancers. The mortality of cervical cancer in low life expectancy level areas was higher than that in other areas. The ASMRW of colorectal and breast cancers in women was higher in high life expectancy level areas than that in low and middle level areas.

Discussion
Life expectancy was adopted by the United Nations General Assembly as an important domain of the Sustainable Development Goals (SDGs) in 2015 [8]. It provides an estimate of the average expected life span under certain conditions, based on current mortality rates. It is the most representative and comprehensive index to judge the social economy and healthcare development of a country or region. Differences in life expectancy were significant across different levels of socioeconomic status, including income [18], education [19] and health services [20].

In the present study, 255 geographical units (cities or counties) were divided into 3 levels based on life expectancy: high, middle and low. The analysis showed the highest crude cancer incidence and mortality rate in high life expectancy level areas, whereas the low life expectancy level areas had the lowest crude cancer incidence and mortality. Areas with higher life expectancy typically have higher incidence and relatively lower mortality [21]. In the present study, the high crude cancer incidence in high life expectancy level areas could be mainly attributed to the high incidence of breast and colorectal cancers (Table 1). The incidence of these cancers is relatively low in less developed and developing countries, but is expected to rise with increasing life expectancy, urbanization, and the adoption of a western lifestyle [22, 23].

Consistent with previous studies [24–26], longer life expectancy was associated with a variety of cancers in the present study, including colorectal, breast, thyroid, prostate and bladder cancers. Coinciding with the transforming cancer trends, these cancers constitute a large burden of disease with the aging population in China [12]. China has undergone rapid demographic and epidemiological changes in the past few decades, including striking declines in fertility and increases in life expectancy at birth [27]. The increase in life expectancy is a key driver of years of life lost (YLLs) and the increases of future burden of cancer [28]. The WHO reported that high income countries (e.g., Japan, Switzerland, Singapore and the US) had an average life expectancy of 80 years or more, but low-middle income countries have greater annual increases in life expectancy [8]. The residents of countries with high living standards have lower mortality rates [1]. In the US, overall cancer death rates have decreased by 25% over the past 2 decades [29]. In China, overall cancer mortality continues to decline while cancer incidence remains relatively stable [2, 28]. In this study, we found highest the ASIRW and the lowest ASMRW in high life expectancy level areas. In contrast, low life expectancy level areas had the highest ASMRW.

Lung cancer remains the most commonly diagnosed cancer and the leading cause of cancer deaths. The incidence of lung cancer was positively associated with life expectancy. Underlying risk factors remain unknown, but could include factors other than ageing itself, including cigarette smoking, air pollution and radon exposure,
### Table 2  Top 10 cancer mortality in three life expectancy levels areas of China, 2013

| Rank | Gender | Low life expectancy level areas | Middle life expectancy level areas | High life expectancy level areas |
|------|--------|---------------------------------|------------------------------------|----------------------------------|
|      |        | Site | Mortality | Proportion | ASR | Site | Mortality | Proportion | ASR | Site | Mortality | Proportion | ASR |
|      |        |      | (1/10^6) | (%)        |     |      | (1/10^6) | (%)        |     |      | (1/10^6) | (%)        |     |
| 0    | Both   | All sites | 156.51 | 100.00 | 118.44 | All sites | 167.98 | 100.00 | 110.99 | All sites | 200.41 | 100.00 | 103.08 |
| 1    |        | Lung | 38.07 | 24.32 | 28.45 | Lung | 46.05 | 27.41 | 29.90 | Lung | 54.93 | 27.41 | 27.49 |
| 2    |        | Stomach | 26.56 | 16.97 | 19.93 | Stomach | 23.32 | 13.88 | 15.15 | Stomach | 22.91 | 11.43 | 11.42 |
| 3    |        | Liver | 24.70 | 15.78 | 18.73 | Liver | 23.32 | 13.88 | 15.15 | Liver | 18.11 | 9.74 | 9.71 |
| 4    |        | Esophagus | 19.21 | 12.28 | 14.38 | Esophagus | 18.21 | 10.84 | 11.77 | Esophagus | 18.53 | 9.25 | 8.94 |
| 5    |        | Colorectum | 8.75 | 5.59 | 6.46 | Colorectum | 10.94 | 6.51 | 7.04 | Colorectum | 15.02 | 9.26 | 8.94 |
| 6    |        | Brain, CNS | 4.14 | 2.64 | 3.35 | Pancreas | 5.36 | 3.19 | 3.51 | Pancreas | 9.69 | 4.83 | 4.86 |
| 7    |        | Breast | 8.48 | 2.64 | 3.35 | Breast | 13.61 | 2.67 | 2.99 | Breast | 12.26 | 3.06 | 3.14 |
| 8    |        | Leukemia | 3.22 | 2.06 | 2.92 | Leukemia | 2.98 | 2.06 | 2.99 | Leukemia | 2.98 | 2.06 | 2.99 |
| 9    |        | Pancreas | 3.18 | 2.03 | 2.88 | Pancreas | 2.98 | 2.06 | 2.99 | Pancreas | 2.98 | 2.06 | 2.99 |
| 10   |        | Cervix | 4.93 | 1.53 | 3.69 | Lymphoma | 3.00 | 1.79 | 2.06 | Lymphoma | 4.67 | 2.33 | 2.24 |
| 0    | Men    | All sites | 194.79 | 100.00 | 154.68 | All sites | 210.95 | 100.00 | 146.69 | All sites | 247.26 | 100.00 | 134.05 |
| 1    |        | Lung | 51.47 | 26.43 | 40.63 | Lung | 61.67 | 29.23 | 42.34 | Lung | 73.50 | 29.73 | 38.95 |
| 2    |        | Stomach | 36.02 | 18.49 | 28.50 | Stomach | 35.78 | 16.96 | 24.95 | Stomach | 30.98 | 12.53 | 16.33 |
| 3    |        | Liver | 35.08 | 18.01 | 27.63 | Liver | 32.11 | 15.22 | 22.16 | Liver | 36.47 | 14.75 | 20.98 |
| 4    |        | Esophagus | 25.50 | 13.09 | 20.26 | Esophagus | 24.98 | 11.84 | 17.23 | Esophagus | 20.80 | 8.41 | 10.76 |
| 5    |        | Colorectum | 9.85 | 5.05 | 7.73 | Colorectum | 12.40 | 5.88 | 8.51 | Colorectum | 15.05 | 7.70 | 10.26 |
| 6    |        | Brain, CNS | 4.60 | 2.36 | 3.84 | Pancreas | 6.01 | 2.85 | 4.16 | Pancreas | 10.72 | 4.33 | 5.77 |
| 7    |        | Pancreas | 3.67 | 1.89 | 2.91 | Pancreas | 4.53 | 2.15 | 3.45 | Pancreas | 6.69 | 2.71 | 3.09 |
| 8    |        | Leukemia | 3.63 | 1.86 | 3.31 | Leukemia | 4.34 | 2.06 | 3.55 | Leukemia | 5.69 | 2.30 | 3.22 |
| 9    |        | Lymphoma | 2.53 | 1.30 | 2.06 | Lymphoma | 3.62 | 1.72 | 2.58 | Lymphoma | 5.62 | 2.27 | 3.74 |
| 10   |        | Bladder | 2.50 | 1.28 | 1.95 | Bladder | 3.10 | 1.47 | 2.09 | Bladder | 4.92 | 1.99 | 3.28 |
| 0    | Women  | All sites | 115.89 | 100.00 | 83.64 | All sites | 123.62 | 100.00 | 77.46 | All sites | 153.33 | 100.00 | 73.37 |
| 1    |        | Lung | 23.84 | 20.57 | 16.78 | Lung | 29.92 | 24.21 | 18.28 | Lung | 36.35 | 23.68 | 16.76 |
| 2    |        | Stomach | 16.53 | 14.26 | 11.6 | Stomach | 14.24 | 11.52 | 8.58 | Stomach | 16.26 | 10.59 | 7.28 |
| 3    |        | Liver | 13.69 | 11.81 | 9.81 | Liver | 12.97 | 10.49 | 8.10 | Liver | 14.83 | 9.66 | 6.91 |
| 4    |        | Esophagus | 12.54 | 10.82 | 8.71 | Esophagus | 11.23 | 9.09 | 6.57 | Esophagus | 12.26 | 9.66 | 6.91 |
| 5    |        | Breast | 8.48 | 7.31 | 6.30 | Colo4rectum | 9.43 | 7.63 | 5.68 | Breast | 12.26 | 7.99 | 6.54 |
| 6    |        | Colo4rectum | 7.58 | 6.54 | 5.29 | Pancreas | 9.12 | 7.38 | 5.99 | Pancreas | 8.65 | 5.64 | 3.98 |
| 7    |        | Cervix | 4.93 | 4.25 | 3.69 | Breast | 4.69 | 3.80 | 2.89 | Esophagus | 6.99 | 4.55 | 2.99 |
| 8    |        | Brain, CNS | 3.64 | 3.14 | 2.87 | Brain, CNS | 3.84 | 3.11 | 2.71 | Breast | 4.97 | 3.24 | 2.20 |
| 9    |        | Uterus | 3.22 | 2.78 | 2.38 | Cervix | 3.65 | 2.96 | 2.38 | Cervix | 4.62 | 3.01 | 2.51 |
| 10   |        | Leukemia | 2.80 | 2.41 | 2.53 | Leukemia | 3.36 | 2.71 | 2.64 | Leukemia | 4.13 | 2.69 | 2.70 |

* ASR: age-standardized mortality rate (Segi’s Standard Population)
as previously suggested by epidemiological studies [30, 31]. With the tobacco epidemic shifting to less developed areas, lung cancer incidence is also increasing in developing regions. Cigarette smoking in China has increased substantially since the 1980s [32]. Smoking is the most important risk factor associated with rising death risks, with 50% of the five million smoking-related deaths worldwide occurring in low- and middle-income countries, and 80% of which are men [33]. In China, the higher rate of smoking was not only in men, but also especially in rural residents [34]. Household air pollution may be another main reason for lung cancer in China, especially in rural areas with the use solid fuels [35].

Breast cancer is the most commonly diagnosed cancer in Chinese women and the disease burden has experienced a rapid growth over the last decade [2, 36]. There is a direct, strong, and meaningful correlation between life expectancy and standardized breast cancer incidence and mortality rates [4]. The age-standardized incidence rate of breast cancer in high life expectancy level areas was 1.6 times as much as that in low life expectancy level areas. Such difference could possibly be attributed to westernization and differences in age at menarche, number of completed births, and other reproductive and hormonal factors [3, 37].

In a previous study, the incidence of colorectal cancer was 6–7 times higher in regions with very high versus low HDI in both sexes [6]. It has been considered one of the clearest markers of transition, as increases in colorectal cancer incidence have generally paralleled increases in human development across most countries [12, 38]. In China, the ASIR of colorectal cancer in urban areas has been reported to be 52% higher than in rural areas [39]. We also observed a positive correlation between life expectancy and the incidence rates of prostate, and pancreatic cancers, but the significance of such association is obscure due to the relatively low incidence rates of these cancers in China [29, 40, 41]. Besides, the incidence of thyroid cancer in high life expectancy level areas was also higher than that in low and middle level areas, likely reflecting improved diagnosis and treatment. Overdiagnosis of thyroid cancer, however, could have also contributed to the association [42, 43]. A finding distinct from that reported in western countries is the fact that cancers of the stomach and liver were major causes of death regardless of life expectancy levels. In contrast to a positive correlation between life expectancy and stomach cancer incidence rate reported by others [25], we did not find any significant correlation between life expectancy and either the incidence or mortality rates of the cancers of the stomach or liver.

The highest ASIR occurred in low life expectancy regions in men, but in high life expectancy regions in women. Such difference could be partially attributed to the higher incidence rates of most common cancers (such as lung, stomach, liver and esophageal cancers) in men in low life expectancy areas (versus in the high life expectancy areas). Factors that influence life expectancy, including health-related behaviors (smoking, obesity, and exercise) and local area characteristics (education, income and government expenditure levels), produce robust impact on the development of cancers [18]. In women, the incidence of breast cancer significantly increased from low life expectancy level areas to high level areas. Ghoncheh’s study showed that the incidence of breast cancer increases with increasing life expectancy, increasing urbanization, and the adoption of a western lifestyle [4]. However, earlier detection may have contributed to the observed increase of incidence for both breast and thyroid cancers [33]. Evidently, the major burden of over diagnosis or overtreatment occurs in women [44]. It is noteworthy that cervical cancer incidence was much higher in low life expectancy level areas in the present study, most likely due to disparities in socioeconomic status and access to high-quality health care [45]. In the 2013 report by the NCCR, the highest mortality rate of cervical cancer was in the northwest and southern rural areas (4.4 per 100,000), with the lowest mortality in eastern urban and northeast rural areas (2.1 per 100,000) [12]. Such geographical distribution pattern is consistent with life expectancy differences across the country [46].

The strength of the present study is its wide coverage of geographical locations and socioeconomic status. The study included data from a total of 255 cities and counties across 31 provinces of China and represented a population of 226.5 million people. However, the sampling was not random. Also, the areas covered by the registry probably had disproportionately high levels of economic development levels, and thus longer life expectancy levels than the national average. Nevertheless, the cancer data used in this study represents the best available nationwide data in China. Moreover, we used the same methods to compare cancer incidence and mortality in three urbanization [47] and GDP [48] levels. These findings may provide an important basis for the next phase of HDI research.

Conclusions

Longer life expectancy is associated with overall rising cancer incidence and mortality in China. However, there is a complex relationship between cancer patterns (incidence, mortality and types) and life expectancy. Ongoing trends, as reflected by differences among cities/counties with varying life expectancy, include a reduction in infection-related cancers (for example, stomach, liver and cervical cancers) and an increase in cancers linked
to a western lifestyle (for example, breast and colorectal cancers). Strategic planning at the governmental level, including the appropriation of resources and programs must be a priority when considering these changes.

Abbreviations
NCCR: National Central Cancer Registry; ASIR: age-standardized incidence rate; ASMR: age-standardized mortality rate; HDI: Human Development Index;
UNDP: United Nations Development Program; NCDC: National Centers for Disease Control and Prevention; IARC/IACR: International Agency for Research on Cancer; International Association of Cancer Registries; CI5: Cancer Incidence in Five Continents.

Authors’ contributions
CWQ contributed to the conception and design of the study proposal. ZRS cleared up the data and performed data analysis. GXY and XCF wrote the article. All authors read and approved the final manuscript.

Author details
1 Cancer Research Institute, Cancer Hospital, Xinjiang Medical University, Urumqi 830011, P. R. China. 2 National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. China.

Acknowledgements
We acknowledged the contribution of the National Central Cancer Registry and its local branches in providing cancer statistics, data collection, sorting, verification and database creation. The authors assume full responsibility for data analyses and interpretation.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All the data supporting the conclusions of this article are included in the article.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Funding
This study was supported by CAMS Innovation Fund for Medical Sciences (2016-2M-2-004), and Ministry of Science and Technology of China (2014FY110010).

Received: 9 January 2018 Accepted:4 June 2018
Published online: 03 July 2018

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.
3. Fidler MM, Soejomotaram I, Bray F. A global view on cancer incidence and national levels of the Human Development Index. Int J Cancer. 2016;139(1):2436–46.
4. Ghoncheh M, Mirzaei M, Salehinya I. Incidence and Mortality of Breast Cancer and their Relationship with the Human Development Index (HDI) in the World in 2012. Asian Pac J Cancer Prev. 2016;16(18):8439–43. https://doi.org/10.7314/apjcp.2015.16.18.8439.
5. Rafiemanesh H, Mehtarpour M, Khami F, Hesami SM, Shamlou R, Towhidiz F, et al. Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world. Asian Pac J Cancer Prev (Apjcp). 2016;17(1):381.
6. Rafiemanesh H, Mohammadianfahshehjani A, Ghoncheh M, Sepehriz N, Shamlou R, Salehinya I, et al. Incidence and mortality of colorectal cancer and relationships with the Human Development Index across the world. Asian Pac J Cancer Prev (Apjcp). 2016;17(15):2465.
7. Horton S, Gauravere GL. Cancer in low- and middle-income countries: an economic overview. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: disease control priorities. 3rd ed. Washington (DC): The World Bank for Reconstruction and Development; 2015.
8. World Health Organization. World health statistics. Monitoring health for the SDGs Sustainable Development Goals. 41st ed. Geneva: World Health Organization; 2016. p. 293–328.
9. Koh HK, Blayke CR, Roper AV. Healthy People 2020. JAMA. 2014;311(24):2475–6.
10. Pe Ntlde la, oacute pe. Human Development Index. Chapters. 2010;8707:3012–3.
11. China NBoSo. Statistical communiqué of the People’s Republic of China on the 2016 National Economic and Social http://www.stats.gov.cn/english/PressRelease/201702/20170228_1467503.html. Accessed 28 Feb 2017.
12. Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71. https://doi.org/10.1016/j.canlet.2017.04.024.
13. Chen W, Zheng R, Zuo T, Zeng H, Zhang S, He J. National cancer incidence and mortality in China, 2012. Chin J Cancer Res. 2016;28(1):1–11. https://doi.org/10.3978/j.issn.1000-9604.2016.02.08.
14. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2014;2(7):61. https://doi.org/10.3978/j.issn.2305-5839.2014.04.05.
15. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):17–30. https://doi.org/10.3322/caac.21332.
16. Curado MF, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer Incidence in Five Continents, vol. IX. Lyon: IARC Scientific Publications; 2008.
17. Cancer IAFRO. IARCrGTools. 2008. http://iarcrorgtolls.software.informer.com/. Accessed 8 May 2018.
18. Chetty R, Steiner M, Abraham S, Lin S, Scuderi B, Turner N, et al. The association between income and life expectancy in the United States, 2001–2014. JAMA. 2016;315(16):1750–66.
19. Hendi AS. Trends in US life expectancy gradients: the role of changing educational composition. Int J Epidemiol. 2015;44(3):946–55.
20. Stenberg K, Hanssen O, Edejer TT, Bertram M, Brindley C, Meshreky A, et al. Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries. Lancet Glob Health. 2017;5(9):e875.
21. Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, et al. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10015):1521–72.
22. Hajmanouchehri F, Asefzadeh S, Kazemifar AM, Eftehaj M. Clinicopathological features of colon adenocarcinoma in Qazvin, Iran: a 16 year study. Asian Pac J Cancer Prev (Apjcp). 2014;15(2):951.
23. World Health Organization. Breast cancer: prevention and control. World Health Stat Ann. 2012;4(1):697–700.
24. Khazaei S, Rezaeian S, Khazaei S, Mansori K, Sanjari MA, Ayubi E. Effects of human development index and its components on colorectal cancer incidence and mortality: a global ecological study. Asian Pac J Cancer Prev (Apjcp). 2016;17:253.
25. Khazaei S, Rezaeian S, Soheylizad M, Khazaei S, Bidarafsh A. Global incidence and mortality rates of stomach cancer and the Human Development Index: an ecological study. Asian Pac J Cancer Prev. 2016;17(4):1701–4.
26. Greiman AK, Rosoff JS, Prasad SM. Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality. BJU Int. 2017;120:799–807.
27. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381(9862):1987–2015.

28. Fitzmaurice C, Dicker D, Pain A, Hanavadi H, Moradi-Lakeh M, Macintyre MF, et al. The global burden of cancer 2013. Jama Oncol. 2015;1(4):505.

29. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):5.

30. Ridge CA, Mcerlean AM, Ginsberg MS. Epidemiology of lung cancer. Chest. 1996;112(1):133.

31. Guo Y, Zeng H, Zheng R, Li S, Barnett AG, Zhang S, et al. The association between lung cancer incidence and ambient air pollution in China: a spatiotemporal analysis. Environ Res. 2016;144(Pt A):60–5.

32. Chen ZM, Peto R, Iona A, Guo Y, Chen YP, Bian Z, et al. Emerging tobacco-related cancer risks in China: a nationwide, prospective study of 0.5 million adults. Cancer. 2015;121(5):3097–106.

33. Freddie Bray SJ. The changing global burden of cancer: transitions in human development and implications for cancer prevention and control. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: disease control priorities, vol. 9. 3rd ed. Washington (DC): The World Bank; 2015. p. 363.

34. Li Q, Hsia J, Yang G. Prevalence of smoking in China in 2010. N Engl J Med. 2011;364(25):2469–70.

35. Wei JS, Hu W, Vermeulen R, Hosgood HD, Downward GS, Chapman RS, et al. Household air pollution and lung cancer in China: a review of studies in Xuanwei. Chin J Cancer. 2014;33(10):471–5.

36. Jia M, Zheng R, Zhang S, Zeng H, Zou X, Chen W. Female breast cancer incidence and mortality in 2011, China. J Thorac Dis. 2015;7(7):1221.

37. Bray F, Mccarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229.

38. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.

39. Liu S, Zheng R, Zhang M, Zhang S, Sun X, Chen W. Incidence and mortality of colorectal cancer in China, 2011. Chin J Cancer Res. 2015;27(1):22.

40. Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–74.

41. Tominaga S. Epidemiology of pancreatic cancer. Semin Surg Oncol. 2016;35(4):3–7.

42. La VC, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136(9):2187.

43. Baker SR, Bhatt WA. The thyroid cancer epidemic: is it the dark side of the CT revolution? Eur J Radiol. 2006;60(1):167–9.

44. Davies L, Welch HG. Current thyroid cancer trends in the United States. Jama Otolaryngol Head Neck Surg. 2014;140(4):317–22.

45. Du P-L, Wu K-S, Fang J-Y, Zeng Y, Xu Z-X, Tang W-R, et al. Cervical cancer mortality trends in China, 1991–2013, and predictions for the future. Asian Pac J Cancer Prev. 2015;16(15):6391–6. https://doi.org/10.7314/apjcp.2015.16.15.6391.

46. Xia C, Ding C, Zheng R, Zhang S, Zeng H, Wang J, et al. Trends in geographical disparities for cervical cancer mortality in China from 1973 to 2013: a subnational spatio-temporal study. Chin J Cancer Res. 2017;29(6):487–95.

47. Chen W, Zheng R, Zhang S, Zeng H, Zuo T, Xiong C, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res. 2017;29(1):1–10. https://doi.org/10.21147/j.issn.1000-9604.2017.01.01.

48. Yang Z, Zheng R, Zhang S, Zeng H, Xia C, Li H, et al. Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013. Chin J Cancer Res (Chung-kuo yen cheng yen chiu). 2017;29(5):385.